(IV) breast cancer according to Site Recode ICD-O-3/WHO 2008 between 2010-2015; (V) belonging to 1 of the 4 subtypes: HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2−; and (VII) either positive or negative metastasis status at diagnosis in lung, bone, liver, brain; ...
Summarized below are key considerations in the use of anti-PD-1/L1 combination approaches for metastatic TNBC, HR-positive breast cancer, and HER2-positive breast cancer. Fig. 1 Potential Mechanisms of synergy of anti-PD-1/L1 combination therapies. a Standard-of-care therapies in the metastatic...
Pyrotinib-based therapy for patients with HER2-positive breast cancer: A multicenter, real-world study. 1040#Background:Pyrotinib, an irreversible pan-ErbB inhibitor, has been approved for the treatment of HER2-positive advanced breast cancer in China. Real-w... H Wang,Y Liu,H Yang,... ...
Mahtani et al Dovepress treatment options have considerably improved outcomes for patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer.5 Chemotherapy is recommended for patients with meta- static breast cancer and is currently the only treatment option for ...
Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer. Pharmacoeconomics. 2014;32(2):135–47. 33. Hannouf MB, Xie B, Brackstone M, ...
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol. 2013;14(2):125–33. Gligorov J, Doval D, Bines J, ...
First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? Article Open access 30 June 2016 Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy? Article 10 July 2023 References...
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol. 2013;14(2):125–33. Gligorov J, Doval D, Bines J, ...
Variants in cell-free DNA of hormone receptor positive, HER2 negative metastatic breast cancer assessed by targeted deep sequencing. Cell. Mol. Life Sci. 2018, submitted. 28. Antonarakis, E.S.; Lu, C.; Luber, B.; Wang, H.; Chen, Y.; Zhu, Y.; Silberstein, J.L.; Taylor, M.N....
HER2-targeted therapy or ≥1 claim for estrogen receptor positive status (ICD-9-CM: V86.0) at any time during their enrollment and ≥2 claims for the same ICD-9-CM codes for another primary malignancy within 30 days of each other and ≥1 days apart (ICD-9-CM: 140.xx-208.22, except...